155 related articles for article (PubMed ID: 18504399)
21. The tyrosine phosphatase SHP2 is required for cell transformation by the receptor tyrosine kinase mutants FIP1L1-PDGFRα and PDGFRα D842V.
Noël LA; Arts FA; Montano-Almendras CP; Cox L; Gielen O; Toffalini F; Marbehant CY; Cools J; Demoulin JB
Mol Oncol; 2014 May; 8(3):728-40. PubMed ID: 24618081
[TBL] [Abstract][Full Text] [Related]
22. Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells.
Verstovsek S; Giles FJ; Quintás-Cardama A; Manshouri T; Huynh L; Manley P; Cortes J; Tefferi A; Kantarjian H
Leuk Res; 2006 Dec; 30(12):1499-505. PubMed ID: 16682077
[TBL] [Abstract][Full Text] [Related]
23. Mechanism of the eosinophilic differentiation of HL-60 clone 15 cells induced by n-butyrate.
Ishihara K; Hong J; Zee O; Ohuchi K
Int Arch Allergy Immunol; 2005; 137 Suppl 1():77-82. PubMed ID: 15947489
[TBL] [Abstract][Full Text] [Related]
24. FIP1L1-PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib.
Wang LN; Pan Q; Fu JF; Shi JY; Jin J; Li JM; Hu J; Zhao WL; Chen Z; Chen SJ
Chin Med J (Engl); 2008 May; 121(10):867-73. PubMed ID: 18706197
[TBL] [Abstract][Full Text] [Related]
25. Leukemogenic kinase FIP1L1-PDGFRA and a small ubiquitin-like modifier E3 ligase, PIAS1, form a positive cross-talk through their enzymatic activities.
Ibata M; Iwasaki J; Fujioka Y; Nakagawa K; Darmanin S; Onozawa M; Hashimoto D; Ohba Y; Hatakeyama S; Teshima T; Kondo T
Cancer Sci; 2017 Feb; 108(2):200-207. PubMed ID: 27960034
[TBL] [Abstract][Full Text] [Related]
26. [Oncogene Fip1-likeL/PDGFRalpha as a target for imatinib in patients with hypereosinophilic syndrome and chronic eosinophilic leukemia. A novel look at pathogenesis and therapy].
Helbig G; Stella-Hołowiecka B; Hołowiecki J
Pol Arch Med Wewn; 2005 May; 113(5):490-7. PubMed ID: 16479834
[No Abstract] [Full Text] [Related]
27. The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-alpha-expressing cells through caspase-3-mediated cleavage of Mcl-1.
Pan J; Quintás-Cardama A; Manshouri T; Giles FJ; Lamb P; Tefferi A; Cortes J; Kantarjian H; Verstovsek S
Leukemia; 2007 Jul; 21(7):1395-404. PubMed ID: 17495975
[TBL] [Abstract][Full Text] [Related]
28. Oncostatin M is a FIP1L1/PDGFRA-dependent mediator of cytokine production in chronic eosinophilic leukemia.
Hoermann G; Cerny-Reiterer S; Sadovnik I; Müllauer L; Bilban M; Gröger M; Horny HP; Reiter A; Schmitt-Graeff A; Mannhalter C; Valent P; Mayerhofer M
Allergy; 2013 Jun; 68(6):713-23. PubMed ID: 23621172
[TBL] [Abstract][Full Text] [Related]
29. ETV6-PDGFRB and FIP1L1-PDGFRA stimulate human hematopoietic progenitor cell proliferation and differentiation into eosinophils: the role of nuclear factor-κB.
Montano-Almendras CP; Essaghir A; Schoemans H; Varis I; Noël LA; Velghe AI; Latinne D; Knoops L; Demoulin JB
Haematologica; 2012 Jul; 97(7):1064-72. PubMed ID: 22271894
[TBL] [Abstract][Full Text] [Related]
30. Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias.
Vandenberghe P; Wlodarska I; Michaux L; Zachée P; Boogaerts M; Vanstraelen D; Herregods MC; Van Hoof A; Selleslag D; Roufosse F; Maerevoet M; Verhoef G; Cools J; Gilliland DG; Hagemeijer A; Marynen P
Leukemia; 2004 Apr; 18(4):734-42. PubMed ID: 14973504
[TBL] [Abstract][Full Text] [Related]
31. [Efficacy of imatinib in FIP1L1-PDGFRA positive hypereosinophilic syndrome].
Menif S; Ben Romdhane N; Hafsia R
Rev Med Interne; 2008 Jan; 29(1):65-7. PubMed ID: 18036706
[TBL] [Abstract][Full Text] [Related]
32. Development of Löffler's endocarditis in FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome despite continuous imatinib mesylate therapy and continuous complete remission.
Václavík J; Szotkowski T; Hutyra M; Kozák J; Lukl J; Táborský M
Am J Hematol; 2010 Apr; 85(4):296-9. PubMed ID: 20169542
[No Abstract] [Full Text] [Related]
33. Comparative proteomic analysis of blood eosinophils reveals redox signaling modifications in patients with FIP1L1-PDGFRA-associated chronic eosinophilic leukemia.
Kahn JE; Dutoit-Lefevre V; Duban-Deweer S; Chafey P; Pottiez G; Lefranc D; Fain O; Cordier JF; Hatron PY; Bletry O; Prin L
J Proteome Res; 2011 Apr; 10(4):1468-80. PubMed ID: 21302907
[TBL] [Abstract][Full Text] [Related]
34. Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome.
Griffin JH; Leung J; Bruner RJ; Caligiuri MA; Briesewitz R
Proc Natl Acad Sci U S A; 2003 Jun; 100(13):7830-5. PubMed ID: 12808148
[TBL] [Abstract][Full Text] [Related]
35. p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells.
Rocchi P; Tonelli R; Camerin C; Purgato S; Fronza R; Bianucci F; Guerra F; Pession A; Ferreri AM
Oncol Rep; 2005 Jun; 13(6):1139-44. PubMed ID: 15870934
[TBL] [Abstract][Full Text] [Related]
36. KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities.
Maric I; Robyn J; Metcalfe DD; Fay MP; Carter M; Wilson T; Fu W; Stoddard J; Scott L; Hartsell M; Kirshenbaum A; Akin C; Nutman TB; Noel P; Klion AD
J Allergy Clin Immunol; 2007 Sep; 120(3):680-7. PubMed ID: 17628645
[TBL] [Abstract][Full Text] [Related]
37. PDGFRalpha/FIP1L1-positive chronic eosinophilic leukemia presenting with retro-orbital localization: efficacy of imatinib treatment.
Vigna E; Lucia E; Gentile M; Mazzone C; Bisconte MG; Gentile C; Armentano A; Ottaviani E; Rondoni M; Martinelli G; Morabito F
Cancer Chemother Pharmacol; 2008 Apr; 61(4):713-6. PubMed ID: 17549478
[TBL] [Abstract][Full Text] [Related]
38. FIP1L1-PDGFR alpha, a therapeutic target for the treatment of chronic eosinophilic leukemia.
Cools J
Verh K Acad Geneeskd Belg; 2005; 67(3):169-76. PubMed ID: 16089297
[TBL] [Abstract][Full Text] [Related]
39. Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosis.
Bain BJ
Am J Hematol; 2004 Sep; 77(1):82-5. PubMed ID: 15307112
[TBL] [Abstract][Full Text] [Related]
40. Multilineage involvement of the fusion gene in patients with FIP1L1/PDGFRA-positive hypereosinophilic syndrome.
Robyn J; Lemery S; McCoy JP; Kubofcik J; Kim YJ; Pack S; Nutman TB; Dunbar C; Klion AD
Br J Haematol; 2006 Feb; 132(3):286-92. PubMed ID: 16409293
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]